Experimental infections with Actinobacillus pleuropneumoniae in pigs--I. Comparison of five different parenteral antibiotic treatments.
SPF pigs aged 10 weeks were infected intranasally with Actinobacillus pleuropneumoniae serotype 2. After the onset of clinical symptoms of respiratory disease, which occurred 20 h post-infection, parenteral treatment with ceftiofur, danofloxacin, enrofloxacin, penicillin or tiamulin was initiated (n = 8 per group). Untreated groups, of which one was infected, served as controls. The uninfected control group did not show any signs of disease, while the infected control group was severely affected by the infection and also expressed a decreased weight gain following the challenge. Based on clinical signs, the magnitude of pathological lesions in the respiratory tract found at necropsy performed 17 days post-infection and the number of reisolates of A. pleuropneumoniae made at necropsy, treatments with the quinolones (danofloxacin and enrofloxacin) and the cephalosporine (ceftiofur) were superior to those with penicillin and tiamulin. The latter groups also developed antibodies to A. pleuropneumoniae to a larger extent. Some of the pigs treated with ceftiofur and danofloxacin developed antibodies to A. pleuropneumoniae, and the microbe was reisolated from approximately 50% of these animals. In contrast, pigs treated with enrofloxacin did not develop antibodies to A. pleuropneumoniae, and the challenge strain was not found at necropsy. The performance with respect to daily weight gain and feed conversion corresponded well with the clinical signs developed and the findings made at necropsy. The decreased growth recorded during the acute phase of the disease was, to a large extent, caused by a reduced feed intake.
Wallgren
P
P
National Veterinary Institute, Uppsala, Sweden.
Segall
T
T
Pedersen Mörner
A
A
Gunnarsson
A
A
D000189:Actinobacillus Infections / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D016977:Actinobacillus pleuropneumoniae / Q000302:isolation & purification; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001835:Body Weight; D002511:Cephalosporins / Q000627:therapeutic use; D004224:Diterpenes / Q000627:therapeutic use; D000077422:Enrofloxacin; D024841:Fluoroquinolones; D008168:Lung / Q000473:pathology; D008171:Lung Diseases / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology / Q000662:veterinary*; D010406:Penicillins / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use; D013552:Swine; D013553:Swine Diseases / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D015430:Weight Gain
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002511:Cephalosporins; D004224:Diterpenes; D024841:Fluoroquinolones; D010406:Penicillins; D015363:Quinolones; C068581:danofloxacin; D000077422:Enrofloxacin; C053503:ceftiofur; C014224:tiamulin